Steroid Injection vs. BioDRestore for Patients With Knee OA
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This study will include patients who are diagnosed with knee OA and are recommended for a
knee injection. Study subjects will be randomized to receive either the standard of care knee
injection (steroid) or amniotic tissue injection (BioDRestore). Study subjects will be asked
for permission for a baseline knee aspiration prior to the knee injection. At 6 months
post-injection, knee aspirations will be taken and sent for analysis. Study subjects will be
followed for 1 year post-injection to include range of motion measurements and
patient-reported pain/functional outcome measurements. X-rays will also be taken at the
1-year post-injection appointment.